Lunsumio Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Lunsumio market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising prevalence of cancer, advancements in diagnosis and screening, increased patient awareness, higher healthcare expenditure, and a growing demand for personalized medicine.

Growth during the forecast period is expected to be driven by the increasing adoption of targeted therapies, an expanding oncology pipeline, rising use of immunotherapies, improved healthcare access, and regulatory support for cancer treatments. Key trends during the forecast period include a heightened emphasis on precision medicine, growth in biosimilar competition, increased use of combination therapies, a shift toward patient-centric care approaches, and strengthening partnerships between biotech and pharmaceutical companies.

The rising prevalence of blood cancer is anticipated to drive the growth of the lunsumio market in the coming years. Blood cancer encompasses cancers that impact the production and function of blood cells, typically originating in the bone marrow or lymphatic system. The most common forms include leukemia, lymphoma, and myeloma. Factors such as an aging population, genetic predisposition, environmental exposures, weakened immune systems, lifestyle choices, and advances in diagnostic techniques contribute to the increasing prevalence of blood cancer. Lunsumio (mosunetuzumab), a bispecific antibody, aids in treating blood cancers such as lymphoma by targeting and binding to cancerous B cells and T cells, enabling the immune system to destroy the cancer cells. It offers an effective treatment option for patients with relapsed or refractory conditions in regions with a high prevalence of blood cancer. For instance, according to Cancer Australia, an Australia-based government agency, an estimated 5,202 new cases of leukemia were diagnosed in 2022, with 3,198 among males and 2,004 among females. Furthermore, the lifetime risk of being diagnosed with leukemia by age 85 is approximately 1 in 58 (1.7%), with a higher risk for males at 1 in 47 (2.1%) compared to females at 1 in 77 (1.3%). Thus, the growing prevalence of blood cancer is fueling the expansion of the lunsumio market.

A significant trend in the lunsumio market is the adoption of innovative therapies, such as bispecific antibodies, to improve treatment efficacy and more precisely target cancer cells. Bispecific antibody therapies are engineered antibodies capable of binding to two targets simultaneously, thereby addressing multiple disease mechanisms and enhancing therapeutic outcomes. For example, in December 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Lunsumio as a treatment for adult patients with relapsed or refractory follicular lymphoma following at least two prior therapies. This approval was based on positive results from the Phase II GO29781 study, which demonstrated the efficacy of lunsumio in heavily pretreated FL patients, including those at high risk of disease progression or refractory to prior treatments.

In October 2024, Lonza Group AG, a Switzerland-based company specializing in pharmaceutical, healthcare, and life sciences manufacturing, acquired the Genentech manufacturing facility from Roche for $1.2 billion. This acquisition aimed to expand Lonza’s production capacity, enhance its technological capabilities, and bolster its position as a leading provider of contract development and manufacturing services for the biopharmaceutical sector. Roche Holding AG, a Switzerland-based pharmaceutical company, developed Lunsumio (mosunetuzumab) as a treatment for relapsed or refractory follicular lymphoma.

The key company operating in the lunsumio market is Roche Holding AG.

North America was the largest region in the lunsumio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lunsumio report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lunsumio market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lunsumio (mosunetuzumab) is a bispecific antibody designed to treat relapsed or refractory follicular lymphoma. It targets CD20 on B-cells and CD3 on T-cells, aiming to boost immune system activity against cancer cells. Approved for patients who have not responded to prior therapies, it offers an innovative approach to cancer immunotherapy.

The primary formulations of lunsumio include an injectable formulation (intravenous) and pre-filled syringes. Injectable formulations in intravenous (IV) form are drugs prepared for direct delivery into the bloodstream. IV formulations of Lunsumio allow for precise dosing and are utilized for patients requiring immediate therapeutic effects. This formulation is particularly preferred in clinical settings for patients with severe conditions. It is indicated for treating relapsed or refractory follicular lymphoma (FL) and other non-Hodgkin lymphomas. The product is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies and is used by end users in hospitals, oncology clinics, specialty pharmacies, and research institutions.

The lunsumio market research report is one of a series of new reports that provides lunsumio market statistics, including the lunsumio industry's global market size, regional shares, competitors with a lunsumio market share, detailed lunsumio market segments, market trends and opportunities, and any further data you may need to thrive in the lunsumio industry. This lunsumio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lunsumio market consists of sales of lunsumio (mosunetuzumab) 30 mg/30m, and lunsumio (mosunetuzumab -axgb) 1mh/ml. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.